Description
Epaidra (Insulin Glulisine) SoloStar Solution for Injections 100 IU/ml. 3 ml. Cartridge №5 + Syringe
Ingredients:
Each ml contains 100 IU of insulin glulisine. Other ingredients include metacresol, glycerol, zinc oxide, hydrochloric acid, and sodium hydroxide.
Mechanism of Action:
Insulin glulisine acts by binding to the insulin receptor, leading to the activation of intracellular signaling pathways that regulate glucose uptake and metabolism in cells.
Pharmacological Properties:
Insulin glulisine is a rapid-acting insulin analog that facilitates the uptake of glucose into cells, thereby lowering blood sugar levels. Its shorter duration of action compared to regular human insulin allows for more precise control of postprandial glucose fluctuations.
Indications for Use:
Epaidra (Insulin Glulisine) is indicated for the treatment of diabetes mellitus in adults and children. It is used to maintain optimal blood glucose levels and reduce the risk of diabetic complications.
Contraindications:
Do not use Epaidra (Insulin Glulisine) if you are allergic to insulin glulisine or any of the other ingredients. Avoid using it during episodes of hypoglycemia or if there are signs of contamination in the solution.
Side Effects:
Common side effects of Epaidra may include hypoglycemia, injection site reactions, allergic reactions, and lipodystrophy at the injection sites.
Usage Instructions:
Prior to administration, visually inspect the solution for any abnormalities. Administer the prescribed dose subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites regularly to prevent tissue damage.
Benefits Compared to Analogues:
Epaidra offers a rapid onset of action and a shorter duration compared to regular human insulin, leading to improved postprandial glucose control and better management of blood sugar levels in patients with diabetes.
Suitable Patient Groups:
Epaidra can be used in both pediatric and geriatric populations under appropriate medical supervision. Dosage adjustments may be necessary based on age, renal function, and other individual factors.
Storage and Shelf Life:
Store Epaidra as per the manufacturer’s instructions. Avoid exposure to extreme temperatures and light. Check the expiration date on the packaging and do not use expired cartridges.
Packaging Description:
Each package of Epaidra contains 5 cartridges of 3 ml solution for injections along with a syringe for administration.
Clinical Evidence and Proven Effectiveness:
Studies have shown that insulin glulisine, the active ingredient in Epaidra, has a rapid onset of action and shorter duration compared to regular human insulin. Clinical trials have demonstrated the efficacy of Epaidra in improving glycemic control in patients with diabetes, making it a valuable option for managing blood sugar levels in both type 1 and type 2 diabetes.
